# A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension

> **NCT07152444** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Uncontrolled Hypertension

## Interventions

- **DRUG:** QLS1410 (CYP11B2 inhibitor)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07152444
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152444, "A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07152444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*